PURPOSE: Skeletal disease causes significant morbidity in mucopolysaccharidoses (MPS), and bone remodeling processes in MPS have not been well characterized. The objective of this study was to determine if biomarkers of bone turnover are abnormal in children with specific MPS disorders (i.e. MSP-I, MPS-II, and MPS-VI) compared to healthy children. METHODS: A cross-sectional study was performed of serum biomarkers of bone formation (bone-specific alkaline phosphatase [BSAP], osteocalcin) and urine biomarkers of bone resorption (pyridinoline, deoxypyridinoline) in MPS and healthy controls. Measures of physical function and pain were obtained using the Children's Health Questionnaire (CHQ). RESULTS: The cohort consisted of 39 children with MPS (MPS-I=26; MPS-II=11; MPS-VI=4) and 51 healthy children. Adjusting for sex and Tanner stage group, MPS individuals had statistically significant increases for osteocalcin (p< 0.001), with trends toward higher BSAP (p=0.054) and urinary pyridinoline (p=0.084). These biomarkers were not significantly associated with CHQ bodily pain and physical-function scores. CONCLUSION: Osteocalcin was increased in children with MPS disorders, with trends for increases in BSAP and urinary pyridinoline, suggesting that bone remodeling is altered in children with MPS. Future studies to assess the ability of these biomarkers to quantify and monitor MPS skeletal disease in response to therapy are needed.
PURPOSE:Skeletal disease causes significant morbidity in mucopolysaccharidoses (MPS), and bone remodeling processes in MPS have not been well characterized. The objective of this study was to determine if biomarkers of bone turnover are abnormal in children with specific MPS disorders (i.e. MSP-I, MPS-II, and MPS-VI) compared to healthy children. METHODS: A cross-sectional study was performed of serum biomarkers of bone formation (bone-specific alkaline phosphatase [BSAP], osteocalcin) and urine biomarkers of bone resorption (pyridinoline, deoxypyridinoline) in MPS and healthy controls. Measures of physical function and pain were obtained using the Children's Health Questionnaire (CHQ). RESULTS: The cohort consisted of 39 children with MPS (MPS-I=26; MPS-II=11; MPS-VI=4) and 51 healthy children. Adjusting for sex and Tanner stage group, MPS individuals had statistically significant increases for osteocalcin (p< 0.001), with trends toward higher BSAP (p=0.054) and urinary pyridinoline (p=0.084). These biomarkers were not significantly associated with CHQ bodily pain and physical-function scores. CONCLUSION:Osteocalcin was increased in children with MPS disorders, with trends for increases in BSAP and urinary pyridinoline, suggesting that bone remodeling is altered in children with MPS. Future studies to assess the ability of these biomarkers to quantify and monitor MPS skeletal disease in response to therapy are needed.
Authors: Brian H Wrotniak; Joan I Schall; Megan E Brault; Dorene F Balmer; Virginia A Stallings Journal: J Pediatr Health Care Date: 2012-11-08 Impact factor: 1.812
Authors: Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman Journal: Proc Natl Acad Sci U S A Date: 2009-12-14 Impact factor: 11.205
Authors: Joseph Muenzer; M Beck; C M Eng; M L Escolar; R Giugliani; N H Guffon; P Harmatz; W Kamin; C Kampmann; S T Koseoglu; B Link; R A Martin; D W Molter; M V Muñoz Rojas; J W Ogilvie; R Parini; U Ramaswami; M Scarpa; I V Schwartz; R E Wood; E Wraith Journal: Pediatrics Date: 2009-11-09 Impact factor: 7.124
Authors: Brianne K Connizzo; Sheila M Adams; Thomas H Adams; David E Birk; Louis J Soslowsky Journal: J Orthop Res Date: 2016-04-07 Impact factor: 3.494
Authors: Brianne K Connizzo; Sheila M Adams; Thomas H Adams; Abbas F Jawad; David E Birk; Louis J Soslowsky Journal: J Biomech Date: 2016-04-02 Impact factor: 2.712
Authors: Gerald V Raymond; Marzia Pasquali; Lynda E Polgreen; Patricia I Dickson; Weston P Miller; Paul J Orchard; Troy C Lund Journal: Sci Rep Date: 2016-12-02 Impact factor: 4.379
Authors: Arin K Oestreich; Mekka R Garcia; Xiaomei Yao; Ferris M Pfeiffer; Sabah Nobakhti; Sandra J Shefelbine; Yong Wang; Amanda C Brodeur; Charlotte L Phillips Journal: Mol Genet Metab Rep Date: 2015-09-07
Authors: Sun H Peck; Yian Khai Lau; Jennifer L Kang; Megan Lin; Toren Arginteanu; Dena R Matalon; Justin R Bendigo; Patricia O'Donnell; Mark E Haskins; Margret L Casal; Lachlan J Smith Journal: Mol Genet Metab Date: 2021-06-15 Impact factor: 4.204